Antibody-drug conjugates — universally known in biotech as ADCs — have become one of the most commercially successful and scientifically active areas of oncology drug development. With multiple blockbuster ADCs on the market and billions in pharmaceutical deal-making driven by ADC pipeline acquisitions, understanding what ADC technology is, how it works, and why the pharmaceutical industry has bet so heavily on it is essential knowledge for any biotech investor covering the oncology space.
The Short Answer
| An antibody-drug conjugate (ADC) is a targeted cancer therapy that combines three components: a monoclonal antibody that recognizes and binds to a protein expressed on the surface of cancer cells, a cytotoxic payload — a potent cancer-killing drug — and a chemical linker that connects the two and controls when the payload is released. The antibody acts as a guided delivery vehicle, targeting the payload specifically to cancer cells expressing the target antigen, reducing the exposure of healthy tissue to the cytotoxic drug compared to conventional chemotherapy. |
The Magic Bullet Concept and Its Long Road to Reality
The concept of a ‘magic bullet’ — a therapeutic agent that would seek out and destroy disease while leaving healthy tissue unharmed — was first proposed by German physician Paul Ehrlich in the early twentieth century. Ehrlich’s vision was prescient, but the technology required to implement it would take another 80 years to develop.
The first ADC approved by the FDA was gemtuzumab ozogamicin (Mylotarg) in 2000, targeting a protein called CD33 expressed in acute myeloid leukemia. Mylotarg had a troubled regulatory history — it was withdrawn in 2010 due to safety and efficacy concerns and then reapproved in 2017 at a lower dose and different dosing schedule, reflecting the iterative nature of early ADC development.
The modern ADC era began with the approval of brentuximab vedotin (Adcetris) in 2011 for Hodgkin lymphoma, followed by ado-trastuzumab emtansine (T-DM1, Kadcyla) in 2013 for HER2-positive breast cancer. The field was transformed by the approval of trastuzumab deruxtecan (Enhertu), developed by Daiichi Sankyo and AstraZeneca, which demonstrated unprecedented efficacy across multiple tumor types and reshaped expectations for what ADCs could achieve.
The Three Components of an ADC and Why Each Matters
The antibody component is the targeting system. It must recognize a protein that is expressed on the surface of cancer cells at higher levels than on normal cells — otherwise the cytotoxic payload will be delivered to healthy tissue, causing toxicity without selectivity. Target selection is one of the most critical strategic decisions in ADC development.
The payload is the cancer-killing component — typically a highly potent cytotoxic agent, often many times more toxic than standard chemotherapy. Because the antibody concentrates the payload at the tumor, ADCs can use payloads too toxic to administer as free drugs. Payloads fall into two main classes: those that damage DNA (such as calicheamicin derivatives) and those that disrupt the cytoskeleton (tubulin-targeting agents such as DM1 and MMAE).
The linker is the chemical connection between the antibody and the payload that determines when and where the payload is released. Stable linkers keep the payload attached in circulation, releasing it only after the ADC is internalized by the cancer cell and the linker is cleaved inside the cell. Cleavable linkers release the payload under conditions specific to the tumor microenvironment. Linker design has been one of the most active areas of ADC engineering — early ADCs had less stable linkers that contributed to systemic toxicity; newer ADC designs have substantially improved linker stability.
Why Enhertu Changed the Field
Trastuzumab deruxtecan (Enhertu), developed through a partnership between Daiichi Sankyo and AstraZeneca, demonstrated something that previous ADCs had not: high efficacy in tumors with low or even heterogeneous target expression, across multiple tumor types simultaneously. It showed significant efficacy in HER2-positive breast cancer, HER2-low breast cancer, HER2-positive gastric cancer, and HER2-expressing non-small cell lung cancer — a breadth of activity unprecedented for a targeted oncology drug.
The commercial and scientific success of Enhertu triggered a wave of pharmaceutical deal-making in ADC assets. Pfizer’s $43 billion acquisition of Seagen — the ADC-focused company behind Adcetris and other approved ADCs — in 2023 was the largest biopharma acquisition of that year, underscoring how strategically important the ADC platform had become to the pharmaceutical industry.
What This Does Not Guarantee
| ADC technology does not guarantee clinical success. ADCs have historically had high rates of serious toxicity — ocular toxicity, interstitial lung disease, hematologic toxicity — particularly when linker or payload design is suboptimal. Many ADC programs in development target the same antigens as approved ADCs; demonstrating differentiation from an established best-in-class product is a genuine clinical and commercial challenge. The field is competitive, rapidly evolving, and subject to the same clinical attrition rates as any other oncology drug class. |
Key Takeaways
- An ADC combines a cancer-targeting antibody, a cytotoxic payload, and a chemical linker — delivering a potent cancer-killing agent specifically to tumor cells
- The concept traces to Paul Ehrlich’s ‘magic bullet’ idea; the first FDA-approved ADC was Mylotarg in 2000, with the modern field defined by approvals from 2011 onward
- Target selection, payload potency, and linker stability are the three critical engineering variables in ADC design
- Trastuzumab deruxtecan (Enhertu) transformed the field by demonstrating high efficacy across multiple tumor types with varying levels of target expression
- Pfizer’s $43 billion acquisition of Seagen in 2023 reflected the strategic value the industry places on proven ADC platforms
- Serious toxicities — including interstitial lung disease and ocular toxicity — are active safety concerns across the ADC drug class
- The ADC space is highly competitive; differentiation from approved best-in-class products is a genuine challenge for clinical-stage programs
Sources
1. FDA — Enhertu (trastuzumab deruxtecan): https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-positive-unresectable
2. NCI — Antibody-Drug Conjugates: https://www.cancer.gov/about-cancer/treatment/drugs/antibody-drug-conjugates
3. FDA — ADC Approvals: https://www.fda.gov/patients/hematologyoncology-cancer-approvals-safety-notifications
4. STAT News: https://www.statnews.com
Disclaimer
This article is based on publicly available regulatory information, company filings, and authoritative industry sources. All information was current as of the date of publication. BioTech Stocks Daily has not received compensation from any company referenced in this article in connection with this coverage.
This article contains references to forward-looking statements and clinical projections. Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those projected. Past clinical results do not guarantee future outcomes.
The information provided in this article is for informational and educational purposes only and does not constitute financial, investment, or medical advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decision.
For full terms, see our Disclaimer.
